表紙
市場調査レポート

潰瘍性大腸炎:パイプライン製品の分析

Ulcerative Colitis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 264709
出版日 ページ情報 英文 260 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
潰瘍性大腸炎:パイプライン製品の分析 Ulcerative Colitis - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 260 Pages
概要

潰瘍性大腸炎 (UC) は、主に大腸に発生する慢性疾患で、炎症性腸疾患の一種です。腸における潰瘍が特徴で、喫煙、遺伝、肝疾患、大腸がん、うつ、重度脱水などの要因があります。一般的な症状は直腸出血、腹部痛、下痢などであり、手術、アミノサリチル酸薬 (ASA製薬) による薬剤治療、免疫調節療法やコルチコステロイドによる治療があります。

当レポートでは、潰瘍性大腸炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

潰瘍性大腸炎の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

潰瘍性大腸炎:企業で開発中の治療薬

潰瘍性大腸炎:大学/機関で研究中の治療薬

潰瘍性大腸炎:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

潰瘍性大腸炎:企業で開発中の製品

潰瘍性大腸炎:大学/機関で研究中の製品

潰瘍性大腸炎の治療薬開発に従事している企業

  • 4D Pharma Plc
  • AbbVie Inc.
  • Advinus Therapeutics Ltd.
  • 味の素 Pharmaceuticals Co., Ltd.
  • Am-Pharma B.V.
  • Amgen Inc.
  • Arena Pharmaceuticals, Inc.
  • Atlantic Healthcare Plc
  • Avaxia Biologics, Inc.
  • BioAtla, LLC
  • Bionovis SA
  • Celgene Corporation
  • Cellceutix Corporation
  • ChemoCentryx, Inc.
  • ChironWells GmbH
  • Chong Kun Dang Pharmaceutical Corp.
  • Coherus BioSciences, Inc.
  • Cosmo Pharmaceuticals S.p.A
  • Dr. Falk Pharma GmbH
  • Effimune S.A.
  • Eli Lilly and Company
  • Enceladus Pharmaceuticals BV
  • enGene, Inc
  • Enterome Bioscience SA
  • Epirus Biopharmaceuticals, Inc.
  • Flexion Therapeutics, Inc.
  • Genentech, Inc.
  • Genor BioPharma Co., Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • GW Pharmaceuticals Plc
  • iCo Therapeutics Inc.
  • Idera Pharmaceuticals, Inc.
  • InDex Pharmaceuticals AB
  • Innovate Biopharmaceuticals, Inc.
  • INOXIA Lifesciences GmbH
  • Intas Pharmaceuticals Ltd.
  • Invion Limited
  • Johnson & Johnson
  • 科研製薬
  • Kymab Limited
  • 協和発酵キリン
  • LIPID THERAPEUTICS GmbH
  • Mabion SA
  • Medestea Research & Production S.p.A.
  • 田辺三菱製薬
  • Momenta Pharmaceuticals, Inc.
  • Morphotek, Inc.
  • Mycenax Biotech Inc.
  • Oncobiologics, Inc.
  • Pfizer Inc.
  • Pluristem Therapeutics Inc.
  • ProtAb Ltd
  • Protagonist Therapeutics Inc.
  • Qu Biologics Inc.
  • Re-Pharm Limited
  • Rebiotix Inc.
  • Sandoz International GmbH
  • Seres Therapeutics, Inc.
  • Sigmoid Pharma Limited
  • Stelic Institute & Co., Inc.
  • sterna biologicals Gmbh & Co KG
  • Synergy Pharmaceuticals, Inc.
  • 武田薬品工業
  • Therapeutic Proteins International, LLC
  • Therapix Biosciences Ltd
  • Theravance Biopharma, Inc.
  • Tillotts Pharma AG
  • Trino Therapeutics Limited
  • Ventria Bioscience

潰瘍性大腸炎:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

潰瘍性大腸炎:最近のパイプライン動向

潰瘍性大腸炎:休止中のプロジェクト

潰瘍性大腸炎:開発が中止された製品

潰瘍性大腸炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7601IDB

Summary

Global Markets Direct's, 'Ulcerative Colitis - Pipeline Review, H1 2016', provides an overview of the Ulcerative Colitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ulcerative Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis
  • The report reviews pipeline therapeutics for Ulcerative Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ulcerative Colitis therapeutics and enlists all their major and minor projects
  • The report assesses Ulcerative Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ulcerative Colitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ulcerative Colitis Overview
  • Therapeutics Development
    • Pipeline Products for Ulcerative Colitis - Overview
    • Pipeline Products for Ulcerative Colitis - Comparative Analysis
  • Ulcerative Colitis - Therapeutics under Development by Companies
  • Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes
  • Ulcerative Colitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Ulcerative Colitis - Products under Development by Companies
  • Ulcerative Colitis - Products under Investigation by Universities/Institutes
  • Ulcerative Colitis - Companies Involved in Therapeutics Development
    • 4D Pharma Plc
    • AbbVie Inc.
    • Advinus Therapeutics Ltd.
    • Ajinomoto Pharmaceuticals Co., Ltd.
    • Am-Pharma B.V.
    • Amgen Inc.
    • Arena Pharmaceuticals, Inc.
    • Atlantic Healthcare Plc
    • Avaxia Biologics, Inc.
    • BioAtla, LLC
    • Bionovis SA
    • Celgene Corporation
    • Cellceutix Corporation
    • ChemoCentryx, Inc.
    • ChironWells GmbH
    • Chong Kun Dang Pharmaceutical Corp.
    • Coherus BioSciences, Inc.
    • Cosmo Pharmaceuticals S.p.A
    • Dr. Falk Pharma GmbH
    • Effimune S.A.
    • Eli Lilly and Company
    • Enceladus Pharmaceuticals BV
    • enGene, Inc
    • Enterome Bioscience SA
    • Epirus Biopharmaceuticals, Inc.
    • Flexion Therapeutics, Inc.
    • Genentech, Inc.
    • Genor BioPharma Co., Ltd.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • GW Pharmaceuticals Plc
    • iCo Therapeutics Inc.
    • Idera Pharmaceuticals, Inc.
    • InDex Pharmaceuticals AB
    • Innovate Biopharmaceuticals, Inc.
    • INOXIA Lifesciences GmbH
    • Intas Pharmaceuticals Ltd.
    • Invion Limited
    • Johnson & Johnson
    • Kaken Pharmaceutical Co., Ltd.
    • Kymab Limited
    • Kyowa Hakko Kirin Co., Ltd.
    • LIPID THERAPEUTICS GmbH
    • Mabion SA
    • Medestea Research & Production S.p.A.
    • Mitsubishi Tanabe Pharma Corporation
    • Momenta Pharmaceuticals, Inc.
    • Morphotek, Inc.
    • Mycenax Biotech Inc.
    • Oncobiologics, Inc.
    • Pfizer Inc.
    • Pluristem Therapeutics Inc.
    • ProtAb Ltd
    • Protagonist Therapeutics Inc.
    • Qu Biologics Inc.
    • Re-Pharm Limited
    • Rebiotix Inc.
    • Sandoz International GmbH
    • Seres Therapeutics, Inc.
    • Sigmoid Pharma Limited
    • Stelic Institute & Co., Inc.
    • sterna biologicals Gmbh & Co KG
    • Synergy Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Therapeutic Proteins International, LLC
    • Therapix Biosciences Ltd
    • Theravance Biopharma, Inc.
    • Tillotts Pharma AG
    • Trino Therapeutics Limited
    • Ventria Bioscience
  • Ulcerative Colitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABS-11 - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • AKP-11 - Drug Profile
    • amiselimod hydrochloride - Drug Profile
    • Anatabine - Drug Profile
    • Antisense RNAi Oligonucleotide to Inhibit microRNA-214 for Ulcerative Colitis and Colon Cancer - Drug Profile
    • AVX-470 - Drug Profile
    • AW/EPO-002 - Drug Profile
    • AW/EPO-003 - Drug Profile
    • AW/EPOPD-01 - Drug Profile
    • AW/EPOPD-02 - Drug Profile
    • AW/EPOPD-06 - Drug Profile
    • brilacidin tetrahydrochloride - Drug Profile
    • CCX-507 - Drug Profile
    • CKD-506 - Drug Profile
    • D-9030 - Drug Profile
    • dolcanatide - Drug Profile
    • Drug to Inhibit Calpain-2 for Crohn's Diseases and Ulcerative Colitis - Drug Profile
    • EFFI-7H - Drug Profile
    • EG-10 - Drug Profile
    • EG-12 - Drug Profile
    • enalaprilat - Drug Profile
    • golimumab biosimilar - Drug Profile
    • golimumab biosimilar - Drug Profile
    • golimumab biosimilar - Drug Profile
    • GSK-2982772 - Drug Profile
    • hyaluronate sodium - Drug Profile
    • IAC VITA - Drug Profile
    • IMO-9200 - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • INN-108 - Drug Profile
    • INV-88 - Drug Profile
    • KANAb-071 - Drug Profile
    • kPPF-1 - Drug Profile
    • KY-1006 - Drug Profile
    • lipidated tacrolimus - Drug Profile
    • Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn's Disease - Drug Profile
    • NRG-4 - Drug Profile
    • ozanimod hydrochloride - Drug Profile
    • P-Dex - Drug Profile
    • PH-44 - Drug Profile
    • PH-46A - Drug Profile
    • PH-5 - Drug Profile
    • PNQ-201 - Drug Profile
    • Prozumab - Drug Profile
    • PTG-100 - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • RBX-2660 - Drug Profile
    • RBX-8225 - Drug Profile
    • Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia - Drug Profile
    • Rosburix - Drug Profile
    • SER-287 - Drug Profile
    • SER-301 - Drug Profile
    • Small Molecule to Agonize S1PR1 for Ulcerative Colitis - Drug Profile
    • Small Molecule to Scavenge Nitric Oxide Radical for Ulcerative Colitis and Inflammation - Drug Profile
    • Small Molecules to Inhibit IL-13 for Ulcerative Colitis - Drug Profile
    • Stem Cell Therapy for Inflammatory Bowel Disease - Drug Profile
    • TAK-114 - Drug Profile
    • TD-1473 - Drug Profile
    • TOP-1288 - Drug Profile
    • TP-10 - Drug Profile
    • VEN-120 - Drug Profile
  • Ulcerative Colitis - Recent Pipeline Updates
  • Ulcerative Colitis - Dormant Projects
  • Ulcerative Colitis - Discontinued Products
  • Ulcerative Colitis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ulcerative Colitis, H1 2016
  • Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Ulcerative Colitis - Pipeline by 4D Pharma Plc, H1 2016
  • Ulcerative Colitis - Pipeline by AbbVie Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Advinus Therapeutics Ltd., H1 2016
  • Ulcerative Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2016
  • Ulcerative Colitis - Pipeline by Am-Pharma B.V., H1 2016
  • Ulcerative Colitis - Pipeline by Amgen Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Arena Pharmaceuticals, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H1 2016
  • Ulcerative Colitis - Pipeline by Avaxia Biologics, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by BioAtla, LLC, H1 2016
  • Ulcerative Colitis - Pipeline by Bionovis SA, H1 2016
  • Ulcerative Colitis - Pipeline by Celgene Corporation, H1 2016
  • Ulcerative Colitis - Pipeline by Cellceutix Corporation, H1 2016
  • Ulcerative Colitis - Pipeline by ChemoCentryx, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by ChironWells GmbH, H1 2016
  • Ulcerative Colitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Ulcerative Colitis - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2016
  • Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2016
  • Ulcerative Colitis - Pipeline by Effimune S.A., H1 2016
  • Ulcerative Colitis - Pipeline by Eli Lilly and Company, H1 2016
  • Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H1 2016
  • Ulcerative Colitis - Pipeline by enGene, Inc, H1 2016
  • Ulcerative Colitis - Pipeline by Enterome Bioscience SA, H1 2016
  • Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Genentech, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Ulcerative Colitis - Pipeline by Gilead Sciences, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Ulcerative Colitis - Pipeline by GW Pharmaceuticals Plc, H1 2016
  • Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Idera Pharmaceuticals, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H1 2016
  • Ulcerative Colitis - Pipeline by Innovate Biopharmaceuticals, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H1 2016
  • Ulcerative Colitis - Pipeline by Intas Pharmaceuticals Ltd., H1 2016
  • Ulcerative Colitis - Pipeline by Invion Limited, H1 2016
  • Ulcerative Colitis - Pipeline by Johnson & Johnson, H1 2016
  • Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016
  • Ulcerative Colitis - Pipeline by Kymab Limited, H1 2016
  • Ulcerative Colitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H1 2016
  • Ulcerative Colitis - Pipeline by Mabion SA, H1 2016
  • Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H1 2016
  • Ulcerative Colitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Ulcerative Colitis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Morphotek, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Mycenax Biotech Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Pfizer Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Pluristem Therapeutics Inc., H1 2016
  • Ulcerative Colitis - Pipeline by ProtAb Ltd, H1 2016
  • Ulcerative Colitis - Pipeline by Protagonist Therapeutics Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Qu Biologics Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Re-Pharm Limited, H1 2016
  • Ulcerative Colitis - Pipeline by Rebiotix Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Sandoz International GmbH, H1 2016
  • Ulcerative Colitis - Pipeline by Seres Therapeutics, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Sigmoid Pharma Limited, H1 2016
  • Ulcerative Colitis - Pipeline by Stelic Institute & Co., Inc., H1 2016
  • Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016
  • Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Ulcerative Colitis - Pipeline by Therapeutic Proteins International, LLC, H1 2016
  • Ulcerative Colitis - Pipeline by Therapix Biosciences Ltd, H1 2016
  • Ulcerative Colitis - Pipeline by Theravance Biopharma, Inc., H1 2016
  • Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H1 2016
  • Ulcerative Colitis - Pipeline by Trino Therapeutics Limited, H1 2016
  • Ulcerative Colitis - Pipeline by Ventria Bioscience, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Ulcerative Colitis Therapeutics - Recent Pipeline Updates, H1 2016
  • Ulcerative Colitis - Dormant Projects, H1 2016
  • Ulcerative Colitis - Dormant Projects (Contd..1), H1 2016
  • Ulcerative Colitis - Dormant Projects (Contd..2), H1 2016
  • Ulcerative Colitis - Dormant Projects (Contd..3), H1 2016
  • Ulcerative Colitis - Dormant Projects (Contd..4), H1 2016
  • Ulcerative Colitis - Dormant Projects (Contd..5), H1 2016
  • Ulcerative Colitis - Dormant Projects (Contd..6), H1 2016
  • Ulcerative Colitis - Dormant Projects (Contd..7), H1 2016
  • Ulcerative Colitis - Dormant Projects (Contd..8), H1 2016
  • Ulcerative Colitis - Discontinued Products, H1 2016
  • Ulcerative Colitis - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Ulcerative Colitis, H1 2016
  • Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top